Hikma Pharmaceuticals (HIK) Price & Analysis

Compare

60 Followers

HIK Stock Chart & Stats

Day’s Range― - ―

52-Week Range1,751.00p - 2,360.00p

Previous CloseN/A

Volume7.28K

Average Volume (3M)450.55K

Market Cap

£4.22B

Enterprise Value5.33B

Total Cash (Recent Filing)£213.00M

Total Debt (Recent Filing)£1.31B

Price to Earnings (P/E)15.1

Beta0.73

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Mar 20, 2025

Dividend Yield3.19%

Share Statistics

EPS (TTM)0.91

Shares Outstanding221,886,460

10 Day Avg. Volume592,154

30 Day Avg. Volume450,550

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£2,503.00

Price Target Upside30.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Earnings GrowthHikma delivered a top of range FY24 print and successfully navigated a tough comp year, delivering a 6% beat to core EBIT compared to guidance at the start of 2024.

Market DemandStrong demand in European and MENA markets, while North America benefits from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio.

Bears Say

Interest ChargesForecasts have been updated to reflect a 2% reduction to FY25 core EBIT and a 5% reduction to adjusted EPS due to higher interest charges.

Sales Mix ImpactThe company expects the phasing and mix of sales to impact margins in the first half, although it maintains a mid-30s core operating margin for FY25.

Hikma Pharmaceuticals News

Hikma Pharmaceuticals Reports Strong H1 2025 Performance and Positive Outlook

An update from Hikma Pharmaceuticals ( ($GB:HIK) ) is now available. Hikma Pharmaceuticals reported solid performance in the...

21h ago

Hikma Pharmaceuticals Issues $500 Million in Guaranteed Notes

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals, through its subsidiary Hikma Finance...

1M ago

Hikma Pharmaceuticals Discloses Managerial Share Disposal

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an announcement. Hikma Pharmaceuticals announced a transaction involving the disposal of...

2M ago

Hikma Pharmaceuticals Discloses Share Disposal by Key Executive

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an update. Hikma Pharmaceuticals announced a transaction involving the disposal of...

2M ago

Hikma Pharmaceuticals Announces Executive Share Vesting Under Incentive Plan

Hikma Pharmaceuticals ( ($GB:HIK) ) has issued an announcement. Hikma Pharmaceuticals PLC announced the vesting of conditional share...

2M ago

Hikma Pharmaceuticals Receives Rating Upgrade from Fitch

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals announced that Fitch has upgraded...

2M ago

Hikma Pharmaceuticals Executives Involved in Share Pledge Transactions

Hikma Pharmaceuticals ( ($GB:HIK) ) has issued an announcement. Hikma Pharmaceuticals PLC has disclosed transactions involving its senior...

3M ago

Hikma Pharmaceuticals Projects Strong Growth and Rebrands Generics Business

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals announced strong medium-term growth guidance...

3M ago

Hikma Pharmaceuticals Executives Acquire Shares Under DRIP

Hikma Pharmaceuticals ( ($GB:HIK) ) has shared an announcement. Hikma Pharmaceuticals announced that several of its Persons Discharging...

3M ago

Hikma Pharmaceuticals’ Credit Rating Upgraded by S&P

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). S&P has upgraded Hikma Pharmaceuticals PLC’s long-term...

3M ago

HIK FAQ

What was Hikma Pharmaceuticals’s price range in the past 12 months?

Hikma Pharmaceuticals lowest share price was 1751.00p and its highest was 2360.00p in the past 12 months.

What is Hikma Pharmaceuticals’s market cap?

Hikma Pharmaceuticals’s market cap is £4.22B.

When is Hikma Pharmaceuticals’s upcoming earnings report date?

Hikma Pharmaceuticals’s upcoming earnings report date is Feb 19, 2026 which is in 195 days.

How were Hikma Pharmaceuticals’s earnings last quarter?

Hikma Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported 0.913p earnings per share for the quarter, the consensus estimate of 0.913p by 0p.

Is Hikma Pharmaceuticals overvalued?

According to Wall Street analysts Hikma Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a Semiannually dividend of 37.001p which represents an annual dividend yield of 3.19%. See more information on Hikma Pharmaceuticals dividends here

What is Hikma Pharmaceuticals’s EPS estimate?

Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals has 221,886,460 shares outstanding.

What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?

Hikma Pharmaceuticals reported an EPS of 0.913p in its last earnings report, expectations of 0.913p. Following the earnings report the stock price went down -6.185%.

Which hedge fund is a major shareholder of Hikma Pharmaceuticals?

Currently, no hedge funds are holding shares in GB:HIK

Hikma Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

15.79%

Trailing 12-Months

Asset Growth

11.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Hikma Pharmaceuticals

Hikma Pharmaceuticals (HIK) is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and non-branded generic and in-licensed pharmaceutical products. Serving both the branded and generic pharmaceutical sectors, the company focuses on critical therapeutic areas such as cardiovascular, respiratory, oncology, and pain management. Hikma operates in multiple regions including the United States, the Middle East and North Africa (MENA), and Europe, positioning itself as a key player in providing accessible and affordable medications globally.

Hikma Pharmaceuticals (HIK) Earnings & Revenues

Historic Earnings Reports

HIK Stock 12 Month Forecast

Average Price Target

2,503.00p

▲(30.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1810":"1,810p","2651":"2,651p","2020.25":"2,020.3p","2230.5":"2,230.5p","2440.75":"2,440.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2650,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.65K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2503,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">2.30K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1810,2020.25,2230.5,2440.75,2651],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1992,2042.6153846153845,2093.230769230769,2143.846153846154,2194.4615384615386,2245.076923076923,2295.6923076923076,2346.3076923076924,2396.923076923077,2447.5384615384614,2498.153846153846,2548.7692307692305,2599.3846153846152,{"y":2650,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1992,2031.3076923076924,2070.6153846153848,2109.923076923077,2149.230769230769,2188.5384615384614,2227.846153846154,2267.153846153846,2306.4615384615386,2345.769230769231,2385.076923076923,2424.3846153846152,2463.6923076923076,{"y":2503,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1992,2015.6923076923076,2039.3846153846155,2063.076923076923,2086.769230769231,2110.4615384615386,2134.153846153846,2157.846153846154,2181.5384615384614,2205.230769230769,2228.923076923077,2252.6153846153848,2276.3076923076924,{"y":2300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1811.92,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1843.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1938.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1877,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1839.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1899.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1957.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2251.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2121.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1948,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1999,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2148,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1992,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >